研討日期 |
2020年3月16日上午10:20~ 12:30 |
研討地點 |
國立臺灣大學609討論室 |
主講題目 Title of the paper |
External Referencing and Pharmaceutical Price Negotiation |
作者 Authors of the paper |
BEGON˜A GARCIA MARIN˜OSO, IZABELA JELOVAC,
and PAU OLIVELLA |
文獻出處 Journal, vol.(issue), pp |
HEALTH ECONOMICS, 20: 737–756 (2011) |
主講人 |
Dong Van Chung |
參加人員 |
Dong Van Chung、王光正、王羿傑、林燕淑、施姵全、梁文榮、張瑞雲、彭正浩、黃鴻、周宗翰、BUI DANG LONG、LUSUNG MKANDAWIRE、DAMIANA SIMANJUNTAK、許至乙 |
摘要 Abstract of the paper |
External referencing (ER) imposes a price cap for
pharmaceuticals, based on prices of identical or comparable products in
foreign countries. Suppose a foreign country (F) negotiates prices with a pharmaceutical firm, whereas a home
country (H) can either negotiate
prices independently or implement ER, based on the foreign price. We show that
country H prefers ER if copayments
in H are relatively high. This
preference is reinforced when H’s
population is small. Irrespective of relative country sizes, ER by country H harms country F. Our model is inspired by the wide European experience with
this cost-containment policy. Namely, in Europe, drug authorization and price
negotiations are carried out by separate agencies. We confirm our main
results in two extensions. The first one allows for therapeutic competition
between drugs. In the second one, drug authorization and price negotiation
take place in a single agency. |